HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Plasma cell leukemia — Clinical Guidelines

Overview

Plasma cell leukemia (PCL) is a rare and aggressive hematologic malignancy characterized by the proliferation of plasma cells in the peripheral blood, often evolving from multiple myeloma or presenting de novo. It is associated with diffuse bone marrow infiltration and can manifest with various clinical complications including hyperviscosity syndrome and cardiac failure 1 6 8 11.

Diagnosis

Key Diagnostic Criteria: Presence of ≥20% plasma cells in peripheral blood or ≥2 × 10^9/L circulating plasma cells 6.

Recommended Tests:

- Bone marrow aspiration showing plasma cell infiltration. - Serum and urine protein electrophoresis to identify monoclonal gammopathy. - Cytogenetic studies to detect clonal chromosomal abnormalities, particularly involving chromosome 1 10.

Imaging: Whole-body MRI with diffusion-weighted imaging can assess diffuse bone marrow infiltration 1.

Management

First-Line Treatments:

- Chemotherapy regimens such as polychemotherapy (e.g., cyclophosphamide, vincristine, doxorubicin, dexamethasone) 9. - Specific drugs like melphalan for achieving remission 3.

Adjunctive Treatments:

- Plasmapheresis for managing hyperviscosity syndrome 5 11. - Supportive care including management of cardiac complications and infections.

Special Populations

Elderly: PCL predominantly affects older adults, with management focusing on tolerability and efficacy of chemotherapy 6.

Comorbidities: Patients often have underlying conditions requiring careful consideration of treatment regimens to avoid exacerbations 8.

Key Recommendations

Diagnosis should include peripheral blood assessment for ≥20% plasma cells or ≥2 × 10^9/L circulating plasma cells (Evidence: Moderate 6).

Cytogenetic analysis, particularly focusing on chromosome 1 abnormalities, is recommended to identify clonal markers (Evidence: Moderate 10).

Chemotherapy, including regimens like melphalan, should be considered for achieving remission in PCL (Evidence: Weak 3 9).

Plasmapheresis is indicated for managing hyperviscosity syndrome associated with PCL (Evidence: Weak 5 11).

Close monitoring and supportive care are essential, especially in elderly patients with comorbidities (Evidence: Expert opinion 8).

References

1 Sun M, Cheng J, Ren C, Zhang Y, Li Y, Wang L et al.. Evaluation of Diffuse Bone Marrow Infiltration Pattern in Monoclonal Plasma Cell Diseases by Quantitative Whole-body Magnetic Resonance Imaging. Academic radiology 2022. link 2 Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 2009. link 3 Ballanti S, Mastrodicasa E, Bolli N, Lotti F, Capolsini I, Berchicci L et al.. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nature clinical practice. Oncology 2007. link 4 Bellan LD, Cox TA, Gascoyne RD. Parasellar syndrome caused by plasma cell leukemia. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 1989. link 5 Kosmo MA, Gale RP. Plasma cell leukemia with IgA paraproteinemia and hyperviscosity. American journal of hematology 1988. link 6 Kosmo MA, Gale RP. Plasma cell leukemia. Seminars in hematology 1987. link 7 Noguchi K, Nagao T, Satoh Y, Kubota T, Shimizu M, Arimori S et al.. Plasma cell leukemia accompanied by polyclonal gammopathy and congenital tumor in the atrioventricular node. The Tokai journal of experimental and clinical medicine 1985. link 8 Tamir R, Lewin RF, Inbal A, Heller I, Theodor E. High-output cardiac failure as a presenting symptom of plasma cell leukemia. Israel journal of medical sciences 1985. link 9 Pacilli L, Ferraro P, Cochi S, De Laurenzi A. Plasma cell leukemia: a report on three patients. Tumori 1983. link 10 Ueshima Y, Fukuhara S, Nagai K, Takatsuki K, Uchino H. Cytogenetic studies and clinical aspects of patients with plasma cell leukemia and leukemic macroglobulinemia. Cancer research 1983. link 11 Douer D, Weinbergerr A, Djaldetti M, Asherov J, Pick I, Pinkhas J. Hyperviscosity syndrome in a patient with plasma cell leukemia. Acta haematologica 1979. link 12 Spiegelberg HL, Heath VC, Lang JE. IgG half-molecules: clinical and immunologic features in a patient with plasma cell leukemia. Blood 1975. link

Plasma cell leukemia